Compare SNEX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNEX | BIO |
|---|---|---|
| Founded | 1924 | 1952 |
| Country | United States | United States |
| Employees | 5400 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 8.0B |
| IPO Year | 1996 | 1994 |
| Metric | SNEX | BIO |
|---|---|---|
| Price | $68.45 | $383.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $81.33 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 966.9K | 275.3K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $132,378,200,000.00 | $2,583,200,000.00 |
| Revenue This Year | N/A | $2.74 |
| Revenue Next Year | $4.17 | $3.20 |
| P/E Ratio | $19.41 | ★ N/A |
| Revenue Growth | ★ 32.53 | 0.65 |
| 52 Week Low | $63.33 | $236.73 |
| 52 Week High | $141.99 | $385.92 |
| Indicator | SNEX | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.50 | 78.90 |
| Support Level | $63.33 | $289.16 |
| Resistance Level | $79.35 | N/A |
| Average True Range (ATR) | 2.70 | 10.41 |
| MACD | 1.77 | 1.72 |
| Stochastic Oscillator | 69.49 | 95.01 |
StoneX Group Inc is a brokerage and financial services firm. Its service offerings are execution, OTC / Market-Making, advisory services, payment solutions, market intelligence, Physical Trading and clearing services. The firm operates in four segments: Commercial, Institutional, Self-Directed/Retail, and Payments. Its customers include governmental and nongovernmental organizations, commercial banks, brokers, institutional investors, and investment banks. The company operates in the United States, South America, Europe, the Middle East and Asia, and other countries, out of which the majority of revenue is generated from the Middle East and Asia Region.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.